Try our Advanced Search for more refined results
Life Sciences
-
December 23, 2025
Top New Jersey Cases Of 2025
New Jersey courts saw some history-making litigation come to a close over the course of 2025, including the largest environmental settlement ever achieved by a single state and the first clergy abuse trial verdict since the statute of limitations on child sexual abuse claims was extended. Another notable development was the state's federal bench exercising a rarely used authority to reject President Donald Trump's pick for interim U.S. attorney.
-
December 23, 2025
Sanofi Eczema Drug Linked To Lymphoma, Suit Says
Drug manufacturers Regeneron Pharmaceuticals and Sanofi were hit with a lawsuit Monday from a Georgia woman alleging the companies have covered up a "strong and consistent causal relationship" between their drug Dupixent and a form of non-Hodgkins lymphoma.
-
December 23, 2025
Baker Botts Hires 2 New DC Partners For Enviro, IP Team
Baker Botts LLP has hired two new partners in its intellectual property and environmental safety and incident response groups, who will both be based in the firm's Washington, D.C., office, Baker Botts said in recent announcements.
-
December 23, 2025
'Gas Station Heroin' Cos. Sued Over User's Overdose
The estate of a woman who died of a tianeptine overdose is suing the makers and sellers of tianeptine products in Pennsylvania state court, saying while they market the products as safe diet supplements, they're actually highly addictive opioids.
-
December 23, 2025
Johnson & Johnson Hit With $1.5B Talc Verdict In Baltimore
A Baltimore jury late Monday returned a walloping verdict of more than $1.5 billion in favor of a woman who claimed that Johnson & Johnson talc products caused her mesothelioma, which her attorneys say is the largest verdict against the company for a single plaintiff.
-
December 22, 2025
Becton Muscles Out Hernia Mesh Rivals, Antitrust Suit Says
Tela Bio Inc. slapped Becton Dickinson and Co. and its subsidiaries with an antitrust lawsuit Friday in Pennsylvania federal court accusing the medical tech giant of abusing its dominant position in the hernia mesh market to block Tela's product and keep Becton's "costlier and clinically inferior" mesh on hospital shelves in the U.S.
-
December 22, 2025
Top Gov't Contracts Cases Of 2025
The Federal Circuit and U.S. Court of Federal Claims ruled on several consequential issues impacting government contractors this year, including deciding who constitutes an "interested party" capable of lodging a bid protest and invalidating a settlement between the Pentagon and one of its major contractors. Here, Law360 reviews the top government contracts-related rulings in 2025.
-
December 22, 2025
Apple Seeks To Overturn $634M Masimo Patent Verdict
Apple has urged a California federal judge to grant its combined motion for judgment or a new trial for its $634 million trial loss over a Masimo patient monitor patent, arguing that no reasonable jury could have reached the verdict and that the tech giant was "severely prejudiced" by erroneous court rulings.
-
December 22, 2025
6th Circ. Vacates Pharma Salesman's $6.8M Restitution Order
The Sixth Circuit vacated a nearly $7 million restitution order against a pharmaceutical salesman convicted of healthcare fraud, finding an Ohio federal court erred in calculating that amount and apportioning liability.
-
December 22, 2025
Fed. Circ. Urged To Preserve Novartis' Bench Trial Loss
MSN Pharmaceuticals has pushed back against Novartis' efforts to save its case accusing the generic-drug maker of infringing a patent covering the blockbuster cardiovascular drug Entresto, telling the Federal Circuit that the appeal "reveals no district court error, just Novartis' poor litigation strategy."
-
December 19, 2025
Colo. IVF Co. Says AI Fertility Co. Owes Nearly $900K
The maker of an in vitro fertilization incubator system has filed a breach of contract lawsuit in Colorado federal court, claiming an artificial intelligence-based fertility company owes it nearly $900,000 for embryoscope incubator systems it sold to the lab.
-
December 19, 2025
AstraZeneca Unit Ducks Patent Fraud, Not Sham Suit Claims
A Massachusetts federal judge spared AstraZeneca unit Alexion on Friday from half of a nonprofit insurer's proposed class action, finding the plaintiff too far removed from anticompetitive patent fraud that allegedly propped up blood disorder treatment Soliris, while preserving accusations that Alexion brought sham infringement allegations against would-be rivals.
-
December 19, 2025
The Top Patent Damages Of 2025
The largest patent verdict of the year was Apple's $634 million loss against Masimo, and juries issued eight other nine-figure verdicts in 2025 — many of which were against Samsung.
-
December 19, 2025
Medical, School Groups Seek Order Halting $100K Visa Fee
A medical practice in rural North Carolina and other employers asked a federal judge Friday to block enforcement of the Trump administration's $100,000 fee on H-1B visas, arguing the "massive" fee hike will inflict irreparable harm on their communities.
-
December 19, 2025
BigLaw And Boutiques Both Shine In 2025's Top 10 Deals
A tight circle of elite law firms guided the way as megadeals roared back with force in 2025, while a small group of specialist and international firms also made their mark across global transactions spanning infrastructure, gaming, pharmaceuticals, artificial intelligence and energy.
-
December 19, 2025
Taxation With Representation: Baker Botts, Morgan Lewis
In this week's Taxation With Representation, Trump Media and Technology Group merges with fusion power company TAE Technologies, pharmaceutical company Cencora boosts its stake in cancer care company OneOncology, and Phoenix Financial partners with private equity giant Blackstone to plug billions into various credit strategies.
-
December 19, 2025
J&J, ChemImage Reach Deal After $77M AI Patent Judgment
Johnson & Johnson has entered an agreement to resolve a lawsuit that ChemImage Corp. had brought alleging the pharmaceutical giant unilaterally ended a deal to develop in-surgery artificial intelligence imaging techniques, after a New York federal judge determined J&J owed $76.6 million in the dispute.
-
December 19, 2025
AbCellera Gets $36M In Cell Research Patent Settlement
Canadian biotechnology firm AbCellera said it had reached a $36 million settlement with Bruker Corp. to resolve patent infringement claims related to a cell analysis system.
-
December 19, 2025
Trump Admin Appeals Harvard Win In $2B Fund Freeze Case
The Trump administration will ask the First Circuit to overturn a federal judge's ruling that prevented the government from withholding $2.2 billion in federal grants from Harvard University over concerns about antisemitism on campus.
-
December 19, 2025
Biomedical Co. Gets Approval For Ch. 11 Auction In January
Eye disease treatment developer Clearside Biomedical on Friday got permission from a Delaware bankruptcy judge for a January auction of its assets after saying it had resolved objections from shareholders and the U.S. Trustee's Office.
-
December 19, 2025
BioMarin Inks $4.8B Amicus Buy As Patent Litigation Resolved
BioMarin Pharmaceutical Inc. has agreed to acquire Amicus Therapeutics for $4.8 billion, in a deal bolstered by Amicus' settlement of patent litigation that secures U.S. exclusivity for its Galafold drug until 2037, the companies said Friday.
-
December 18, 2025
The Biggest Rulings From A Busy Year At The 1st Circ.
The nation's smallest federal appellate panel punched above its weight in 2025, grappling with numerous suits against the Trump administration, high-profile criminal appeals, a $34 million legal fee bid and a hotly contested kickback law.
-
December 18, 2025
ITC Clears Toy Gun Imports, Will Review Smart Rings, Vapes
The U.S. International Trade Commission has had a busy week in intellectual property, determining a series of toy gun imports don't infringe Spin Master patents licensed to Hasbro, instituting reviews requested by companies including Ouraring, AbbVie and Juul, and receiving several new complaints.
-
December 18, 2025
Eli Lilly Workers Say Justices Needn't Mull Collective Standard
Eli Lilly workers on Wednesday pressed the U.S. Supreme Court not to disturb a Seventh Circuit decision establishing a new, more flexible standard for certifying collective actions, arguing that there's no "urgent" need for the high court to weigh in on the dispute.
-
December 18, 2025
InnovAge Investors Get Final OK For $27M Deal, Atty Fees
A Colorado federal judge has granted final approval to a $27 million settlement between InnovAge Holding Corp., its underwriters and a class of stockholders accusing the senior healthcare company of making misleading statements in an initial public offering that later caused stock prices to tank after a government audit exposed the alleged falsehoods.
Expert Analysis
-
9th Circ.'s Kickback Ruling Strengthens A Prosecutorial Tool
The Ninth Circuit's decision last month in U.S. v. Schena, interpreting the Eliminating Kickbacks in Recovery Act to prohibit kickback conduct between the principal and individuals who do not directly interact with patients, serves as a wake-up call to the booming clinical laboratory testing industry, say attorneys at Kendall Brill.
-
Series
Law School's Missed Lessons: How To Make A Deal
Preparing lawyers for the nuances of a transactional practice is not a strong suit for most law schools, but, in practice, there are six principles that can help young M&A lawyers become seasoned, trusted deal advisers, says Chuck Morton at Venable.
-
From Clerkship To Law Firm: 5 Transition Tips For Associates
Excerpt from Practical Guidance
Transitioning from a judicial clerkship to an associate position at a law firm may seem daunting, but by using knowledge gained while clerking, being mindful of key differences and taking advantage of professional development opportunities, these attorneys can flourish in private practice, say attorneys at Lowenstein Sandler.
-
9th Circ.'s Trade Secrets Ruling Is A Win For DTSA Plaintiffs
The Ninth Circuit's recent decision in Quintara v. Ruifeng shifts the balance in federal trade secret litigation toward a more flexible, discovery-driven process, meaning that plaintiffs may be more likely to pursue claims under the Defend Trade Secrets Act, and early motions to strike or dismiss will face steep odds, say attorneys at Cooley.
-
Associates Can Earn Credibility By Investing In Relationships
As the class of 2025 prepares to join law firms this fall, new associates must adapt to office dynamics and establish credible reputations — which require quiet, consistent relationship-building skills as much as legal acumen, says Kyle Forges at Bast Amron.
-
Puzzling Out When Similar Insurance Claims Are Related
A recent decision in Virginia federal court shows that more than identical allegations of negligent business practices across two lawsuits may be necessary to satisfy the strict definition of relatedness under claims-made liability insurance policies, say attorneys at Hunton.
-
A Shifting Trend In FDA Form 483 Disclosure Obligations
A New York federal court's Checkpoint Therapeutics decision extends a recent streak of dismissals of securities class actions alleging that pharmaceutical companies failed to disclose U.S. Food and Drug Administration Form 483 inspection reports, providing critical guidance for companies during the FDA approval process, say attorneys at Alston & Bird.
-
Trending At The PTAB: IPR Memo And Its Fed. Circ. Backdrop
There are new rules for when and how evidence other than patents or printed publications can be considered in inter partes reviews, and while this change is intended to reflect current Federal Circuit precedent, the U.S. Patent and Trademark Office's memo seems to acknowledge tension with last month's Shockwave decision, say attorneys at Finnegan.
-
Lessons From 7th Circ.'s Deleted Chat Sanctions Ruling
The Seventh Circuit’s recent decision in Pable v. Chicago Transit Authority, affirming the dismissal of an ex-employee’s retaliation claims, highlights the importance of properly handling the preservation of ephemeral messages and clarifies key sanctions issues, says Philip Favro at Favro Law.
-
Breaking Down The Proposed Hemp Bill
A proposed bill in the U.S. House of Representatives, recently approved by the House Appropriations Committee, contains a rider that would significantly change the definition of hemp and dramatically reshape the current hemp-derived product market, say attorneys at King & Spalding.
-
Assessing Federal Securities Class Action Stats In '25 So Far
The settlement amount as a percentage of damages in securities class actions has continued to decline in the first half of 2025, a trend that may be important for assessing exposure and risk in future securities litigation, say analysts at Analysis Group.
-
Series
Quilting Makes Me A Better Lawyer
Turning intricate patterns of fabric and thread into quilts has taught me that craftsmanship, creative problem-solving and dedication to incremental progress are essential to creating something lasting that will help another person — just like in law, says Veronica McMillan at Kramon & Graham.
-
How Agentic AI Is Testing The Limits Of Patent Law
While a recent Swiss court ruling suggests that human-centric rules regarding inventorship will likely remain in place for the near future, it captures a core tension confronting patent systems worldwide as the technology producing patent-worthy ideas is becoming increasingly autonomous, says Matthew Carey at Marshall Gerstein.
-
How To Prep For Potential Passage Of SAFER Banking Act
The Secure and Fair Enforcement Regulation, or SAFER, Banking Act, could fundamentally reshape how financial institutions interact with cannabis businesses, so operators that move now to get their house in order will be best positioned to capitalize if and when change comes, says Alex Leonowicz at Howard & Howard.
-
A Former PTAB Judge Weighs The End Of Remote Hearings
Former Patent Trial and Appeal Board Judge Amanda Wieker, now at McGuireWoods, examines the costs and benefits of the PTAB's impending in-person hearing requirement, and offers suggestions for making the most out of this new regime.